These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32389126)

  • 1. Clinical utility of cardiovascular magnetic resonance imaging in patients with implantable cardioverter defibrillators presenting with electrical instability or worsening heart failure symptoms.
    Lindemann F; Oebel S; Paetsch I; Arya A; Dagres N; Richter S; Dinov B; Hilbert S; Loebe S; Stegmann C; Doering M; Bollmann A; Hindricks G; Jahnke C
    J Cardiovasc Magn Reson; 2020 May; 22(1):32. PubMed ID: 32389126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience regarding safety and diagnostic value of cardiovascular magnetic resonance in patients with a subcutaneous implanted cardioverter/defibrillator (S-ICD) at 1.5 T.
    Holtstiege V; Meier C; Bietenbeck M; Chatzantonis G; Florian A; Köbe J; Reinke F; Eckardt L; Yilmaz A
    J Cardiovasc Magn Reson; 2020 May; 22(1):35. PubMed ID: 32418537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance.
    Champ-Rigot L; Gay P; Seita F; Benouda L; Morello R; Pellissier A; Alexandre J; Saloux E; Milliez P
    J Cardiovasc Magn Reson; 2020 Jun; 22(1):48. PubMed ID: 32580786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible Cause of Cardiac Arrest and Secondary Prevention Implantable Cardioverter Defibrillators in Patients With Coronary Artery Disease: Value of Complete Revascularization and LGE-CMR.
    van der Lingen ACJ; Becker MAJ; Kemme MJB; Rijnierse MT; Spoormans EM; Timmer SAJ; van Rossum AC; van Halm VP; Germans T; Allaart CP
    J Am Heart Assoc; 2021 Apr; 10(8):e019101. PubMed ID: 33821672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infarct tissue characterization in implantable cardioverter-defibrillator recipients for primary versus secondary prevention following myocardial infarction: a study with contrast-enhancement cardiovascular magnetic resonance imaging.
    Olimulder MA; Kraaier K; Galjee MA; Scholten MF; van Es J; Wagenaar LJ; van der Palen J; von Birgelen C
    Int J Cardiovasc Imaging; 2013 Jan; 29(1):169-76. PubMed ID: 22684301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
    Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complexity of scar and ventricular arrhythmias in dilated cardiomyopathy of any etiology: Long-term data from the SCARFEAR (Cardiovascular Magnetic Resonance Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy Delivery) Registry.
    Pedretti S; Vargiu S; Baroni M; Dellegrottaglie S; Lanzarin B; Roghi A; Milazzo A; Quattrocchi G; Lunati M; Pedrotti P
    Clin Cardiol; 2018 Apr; 41(4):494-501. PubMed ID: 29663442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMR DENSE and the Seattle Heart Failure Model Inform Survival and Arrhythmia Risk After CRT.
    Bilchick KC; Auger DA; Abdishektaei M; Mathew R; Sohn MW; Cai X; Sun C; Narayan A; Malhotra R; Darby A; Mangrum JM; Mehta N; Ferguson J; Mazimba S; Mason PK; Kramer CM; Levy WC; Epstein FH
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):924-936. PubMed ID: 31864974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of wideband cardiac magnetic resonance on diagnosis, decision-making and outcomes in patients with implantable cardioverter defibrillators.
    Patel HN; Wang S; Rao S; Singh A; Landeras L; Besser SA; Carter S; Mishra S; Nishimura T; Shatz DY; Tung R; Nayak H; Kawaji K; Mor-Avi V; Patel AR
    Eur Heart J Cardiovasc Imaging; 2023 Jan; 24(2):181-189. PubMed ID: 36458878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC; Gerstenblith G; Guallar E; Marine JE; Dalal D; Cheng A; Marbán E; Lima JA; Tomaselli GF; Weiss RG
    Circ Cardiovasc Imaging; 2012 Mar; 5(2):178-86. PubMed ID: 22267750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left Ventricular Entropy Is a Novel Predictor of Arrhythmic Events in Patients With Dilated Cardiomyopathy Receiving Defibrillators for Primary Prevention.
    Muthalaly RG; Kwong RY; John RM; van der Geest RJ; Tao Q; Schaeffer B; Tanigawa S; Nakamura T; Kaneko K; Tedrow UB; Stevenson WG; Epstein LM; Kapur S; Zei PC; Koplan BA
    JACC Cardiovasc Imaging; 2019 Jul; 12(7 Pt 1):1177-1184. PubMed ID: 30121262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term benefit of first-line peri-implantable cardioverter-defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients.
    Acosta J; Cabanelas N; Penela D; Fernández-Armenta J; Andreu D; Borràs R; Korshunov V; Cabrera M; Vasanelli F; Arbelo E; Guasch E; Martínez M; Tolosana JM; Mont L; Berruezo A
    Europace; 2017 Jun; 19(6):976-982. PubMed ID: 27353322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease.
    Alexandre J; Saloux E; Dugué AE; Lebon A; Lemaitre A; Roule V; Labombarda F; Provost N; Gomes S; Scanu P; Milliez P
    J Cardiovasc Magn Reson; 2013 Jan; 15(1):12. PubMed ID: 23331500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators.
    Sadarmin PP; Wong KC; Rajappan K; Bashir Y; Betts TR
    Europace; 2014 Nov; 16(11):1575-9. PubMed ID: 24668515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scar heterogeneity on cardiovascular magnetic resonance as a predictor of appropriate implantable cardioverter defibrillator therapy.
    Rayatzadeh H; Tan A; Chan RH; Patel SJ; Hauser TH; Ngo L; Shaw JL; Hong SN; Zimetbaum P; Buxton AE; Josephson ME; Manning WJ; Nezafat R
    J Cardiovasc Magn Reson; 2013 Apr; 15(1):31. PubMed ID: 23574733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation.
    Joshi SB; Connelly KA; Jimenez-Juan L; Hansen M; Kirpalani A; Dorian P; Mangat I; Al-Hesayen A; Crean AM; Wright GA; Yan AT; Leong-Poi H
    J Cardiovasc Magn Reson; 2012 Oct; 14(1):69. PubMed ID: 23043729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.